DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview

BACKGROUND: In clinical oncology, systemic 5‐fluorouracil (5‐FU) and its oral pro‐drugs are used to treat a broad group of solid tumours. Patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency are at elevated risk of toxicity if treated with standard doses of 5‐FU. DPYD genotyping and...

Descripción completa

Detalles Bibliográficos
Autores principales: Paulsen, Niels Herluf, Vojdeman, Fie, Andersen, Stig Ejdrup, Bergmann, Troels K., Ewertz, Marianne, Plomgaard, Peter, Hansen, Morten Rix, Esbech, Peter Skov, Pfeiffer, Per, Qvortrup, Camilla, Damkier, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
MINI REVIEWS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826411/
https://www.ncbi.nlm.nih.gov/pubmed/35997509
http://dx.doi.org/10.1111/bcpt.13782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826411/
https://www.ncbi.nlm.nih.gov/pubmed/35997509
http://dx.doi.org/10.1111/bcpt.13782

Ejemplares similares